GLOW

GLOW is a vendor name for a three-peptide mixture, GHK-Cu, BPC-157, and TB-500, usually sold as a 70 mg total vial. It is KLOW without the KPV. The stated composition varies between suppliers (35 to 50 mg of GHK-Cu, 5 to 10 mg of BPC-157, alongside a more consistent 10 mg of TB-500), which means GHK-Cu’s share ranges from roughly 70 to 78 percent of the vial depending on the source. No study has tested the three components together in any system, and the same unanswered copper-interaction question that applies to KLOW applies here, more so, since GHK-Cu is an even larger share of this mixture.

Research snapshot

Peptide category	Three-component peptide blend (GHK-Cu + BPC-157 + TB-500)
Primary research interest	Skin appearance and recovery (as marketed; not established for the combination)
Highest available evidence	None for the three-component blend itself; the closest adjacent data is a two-component (BPC-157 + TB-500) animal study
Human research available	No, zero human data exists for the three-component combination
Development status	Not a formulated drug product; a compounding/vendor mixture only
Regulatory status	None of the three components approved for human use anywhere; BPC-157, TB-500 and injectable GHK-Cu nominations were withdrawn at FDA in April 2026; none is approved

Technical identity (composition)

Primary name	GLOW
Alternative names	None beyond the component-based name itself; effectively “KLOW without the KPV”
Composition	GHK-Cu 35–50 mg, BPC-157 5–10 mg, TB-500 10 mg, commonly sold as a 70 mg total vial, reconstituted in 3 mL; documented composition varies by supplier
Share of vial by mass	GHK-Cu ~70–78%, BPC-157 ~11–14%, TB-500 ~14–20%, depending on the source
Peptide sequence	Not applicable, a multi-component mixture; see each component’s own entry for its sequence
Molecular formula	Not applicable, a multi-component mixture
CAS Registry Number	Not applicable, a multi-component mixture, not a single registered substance
Chemical modifications	Not applicable at the blend level; see each component’s own entry
Peptide class	Vendor-formulated multi-peptide mixture
Primary biological target	Multiple, inherits each component’s own separately-proposed target (see each component’s entry)
Developer or originator	Not a formal pharmaceutical development program, a research-chemical/compounding vendor mixture
Development status	Not in any clinical development pathway

What it is

GLOW is a vendor name for three peptides in one vial: GHK-Cu, BPC-157 and TB-500. It is KLOW without the KPV. Usually sold as a 70 mg total-peptide vial reconstituted in 3 mL.

The commonly stated split is GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg, which puts GHK-Cu at about 71 percent of the vial by mass. Variance is documented: at least one source gives 35 to 50 mg of GHK-Cu and 5 mg of BPC-157, so the share of the copper peptide ranges from roughly 70 to 78 percent depending on whose vial it is.

The name is marketing, aimed at skin. Nothing in the research literature connects these three compounds to each other or to a cosmetic endpoint.

GLOW, KLOW and Wolverine are not the same thing

These three names are searched together, sold alongside each other, and routinely confused. Stated plainly:

• GLOW is GHK-Cu plus BPC-157 plus TB-500.
• KLOW is those three plus KPV, usually at 80 mg total rather than 70 mg.
• Wolverine contains no GHK-Cu and no KPV. It is BPC-157 and TB-500 only.

The practical consequence is that a reader who has compared protocols across the three names has been comparing figures for different mixtures, at different total masses, with the dominant component in two of them being a copper compound that is absent from the third.

Potential benefits and research applications

Skin and recovery (the marketed premise)

What is being investigated: nothing specific to this three-component combination, no study has tested it. How the effect might occur: by combining GHK-Cu’s proposed tissue-remodeling signaling with BPC-157’s and TB-500’s proposed tissue-repair mechanisms. Evidence: none for the combination; the nearest data point is the two-component BPC-157/TB-500 study (Bicer 2026), which does not include GHK-Cu and found no added benefit from combining even those two alone. Strength: none established. Limitation: three compounds with individually incomplete evidence, one of which (GHK-Cu) has its strongest human evidence pointing to no benefit over placebo in a controlled trial, do not add up to a validated combination.

Component-level claims

GHK-Cu, at up to about 78 percent of this vial, is the component most heavily marketed for skin, but its strongest human evidence, a randomized placebo-controlled trial in 86 venous-ulcer patients, found no benefit over placebo. BPC-157 and TB-500 each carry their own separately documented, generally preliminary evidence. None of this transfers automatically to a three-peptide mixture that has never itself been tested.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objective	Route reported	Amount reported	Frequency reported	Reported duration	Evidence or source category
Skin and recovery (blend as sold)	Subcutaneous	10 units (~0.10 mL) of reconstituted vial	Once daily	4–6 weeks on, 2–4 off	Community/vendor reported
GHK-Cu delivered per dose	Subcutaneous	~1.67 mg	Once daily	4–6 weeks	Community/vendor reported (derived from vial math, 50/10/10 split)
BPC-157 and TB-500 delivered per dose (each)	Subcutaneous	~333 mcg each	Once daily	4–6 weeks	Community/vendor reported (derived from vial math)

Not consistently reported: any dosage for the three-component combination from a controlled study of any kind, human or animal; a single fixed composition (documented range: 35–50 mg GHK-Cu, 5–10 mg BPC-157 depending on supplier). The GHK-Cu and BPC-157 delivered amounts land inside their own separately-circulating conventions, but the TB-500 figure (~333 mcg/day) is far below its own ~2–5 mg weekly convention, a mismatch no vendor material addresses.

What is known about the combination

Nothing. No study has tested these three together in any system or species. No clinical trial and no registered trial exists.

The only combination data anywhere near this blend is the rat Achilles study that tested two of the three, BPC-157 and TB-500, and found the combination no better than TB-500 on its own.

The copper question that applies to KLOW applies here too, and more so, because GHK-Cu is an even larger share of this vial. Nobody has published on whether the copper stays on the GHK in a shared solution, or on whether its presence accelerates degradation of the two peptides sitting alongside it. Copper catalyses oxidation and both of the others are peptides in water.

What the component evidence says

• GHK-Cu, at about 71 percent of the vial, has one real randomised placebo-controlled human trial, in 86 patients with venous ulcers, and it found the compound no better than placebo. The positive human material for it is conference abstracts and a press release. The paper cited everywhere for its hair claims tested a different peptide.
• BPC-157 has no identified receptor, a literature 77 percent authored by one laboratory, and three uncontrolled human reports from one clinic.
• TB-500 is not thymosin beta-4, has no human study of any kind, and was inactive in the one wound assay that tested the actual molecule.

Regulatory status

None of the three is an approved drug anywhere. BPC-157 and TB-500 were each the subject of FDA nominations that were later withdrawn, with immunogenicity noted as the concern. For GHK-Cu, FDA’s 503A categories page dated May 14, 2026 lists it in Category 1 (substances under evaluation) except for injectable routes, so the injectable form used in this blend has no active nomination, and withdrawal is not a clearance. FDA says it intends to consult its advisory committee on GHK-Cu before the end of February 2027. On 23 July 2026 that committee recommended BPC-157 and TB-500 for the 503A list in a non-binding vote against FDA staff; GHK-Cu was not among the substances voted on.

TB-500 is named in WADA section S2.3 and prohibited at all times. BPC-157 falls under class S0. GHK-Cu is cleared for cosmetic use at industry concentrations, which are three to five orders of magnitude below what circulates, and that clearance has nothing to do with injection.

Frequently asked questions

What is GLOW?

A vendor name for a mixture of GHK-Cu, BPC-157, and TB-500, usually sold as a 70 mg vial.

Is GLOW the same as KLOW?

No. GLOW is KLOW without the KPV.

Is GLOW the same as Wolverine?

No. Wolverine has no GHK-Cu.

How much GHK-Cu is actually in it?

Commonly stated as 50 mg of a 70 mg vial (about 71%), though sources document a range of 35 to 50 mg, so the actual share varies by supplier.

Has the combination been studied?

No. No study, human or animal, has tested all three together.

How is it dosed?

Commonly 10 units (about 0.10 mL) of the reconstituted vial daily, a vendor convention with no study behind the schedule.

Is it approved for any use?

No. None of the three components is an approved drug for injectable use; GHK-Cu has cosmetic clearance only at concentrations far below what this blend delivers.

What remains unknown?

Whether the copper interacts with the other two peptides, whether the composition is actually consistent between suppliers, and whether the combination does anything as a whole.

Is it banned in sports?

TB-500 is explicitly named and prohibited at all times under WADA; BPC-157 also falls under a prohibited category.

Bottom line

GLOW is KLOW with one ingredient removed, marketed specifically toward skin appearance, and, like KLOW, it has never been tested as a combination in any study. GHK-Cu dominates the vial by mass more here than in KLOW (up to about 78% by some vendor formulations), which makes the unanswered copper-interaction question more relevant, not less. The documented composition range (35-50 mg GHK-Cu, 5-10 mg BPC-157) means the “70 mg vial” name doesn’t guarantee a consistent product between suppliers. What circulates is entirely vendor- and community-derived, built by combining each component’s separately invented convention, and those conventions don’t reconcile within one fixed-ratio dose. All three components remain unapproved for injectable human use.